Akeso’s lung cancer drug reduces death risk by 34%, marking the first Chinese drug at ASCO’s top stage in 61 years

Akeso, the Chinese biotechnology company whose drug ivonescimab was dubbed “biotech’s DeepSeek moment” last year, has reported phase three clinical trial results showing a 34% reduction in the risk of death for patients with advanced squamous non-sma...